Linagliptin is a novel, potent, and selective dipeptidyl peptidase-4 (DPP-4) inhibitor primarily used in the treatment of type 2 diabetes mellitus. 

Basic Information

• English Name: Linagliptin

• CAS Number: 668270-12-0

• Molecular Formula: C25H28N8O2

• Molecular Weight: 472.54

Pharmacological Action

Linagliptin inhibits the activity of DPP-4, thereby increasing the concentrations of active incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones participate in the physiological regulation of glucose homeostasis, stimulating insulin release in a glucose-dependent manner and reducing circulating glucagon levels.

Indications

Linagliptin is indicated for the treatment of type 2 diabetes mellitus. It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. It can be used alone or in combination with other antidiabetic agents, such as metformin, to achieve better glycemic control.